64Cu-SAR-bisPSMA not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.”In the company’s words, NCT06056830 on ClinicalTrials.gov
- Tested for
- Prostate Cancer (2 trials), Prostatic Neoplasms, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant, Prostate Cancer Patients Treated by Radiotherapy, Cryotherapy, Prostatic Neoplasms, Castration-Resistant
- Main trialPhase 3
- “The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.”In the company’s words, NCT06056830 on ClinicalTrials.gov
Other drugs for Prostate Cancer
- ApalutamideJanssen Research & Development, LLC · Phase 3
- Abiraterone acetateJanssen Research & Development, LLC · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
- Aglatimagene besadenovecCandel Therapeutics · Phase 3
Coming up1
- 31 DecPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Sep 2026 | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy | |
| Phase 3Active, not recruiting | 31 Dec 2026 | 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | |
| Phase 1/2Recruiting | Sep 2026 | 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) | |
| Phase 1/2Completed | 8 Aug 2023 | 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA) | |
| Phase 1Completed | 19 Oct 2022 | Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026